BRAF and melanoma: The Pan-RAF inhibitor L-779,450 which suppresses cell proliferation in melanoma cell lines both with mutated B-Raf and with wild-type B-Raf [32], BMS-345541, an IKK-2 inhibitor that addresses the NF-kappaB pathway and has antiinflammatory properties and Aurora kinase an inhibitor MLN-8237 (AKA-I), which inhibits a member of the novel family of Aurora serine/threonine kinases crucial for cell cycle control [33].